A recent study found that while treatment outcomes for a CLL therapy are comparable in clinical trials and the real-world setting, adverse events are increased in the latter.
Laws designed to equalize out-of-pocket costs faced by cancer patients undergoing chemotherapy — whether treated intravenously, with pills or liquid doses — are having mixed results.
Duke Cancer Institute has developed a community health program focused on minimizing cancer disparities and improving overall health.
Patients with cancer receiving radiation therapy who have a previous psychiatric diagnosis have 208% higher follow-up emergency department costs than patients without a pre-existing psychiatric diagnosis.
Patients with hepatocellular carcinoma who took a reduced therapy dose had a lower cumulative pill cost and were less likely to discontinue treatment due to toxicities.
Researchers compared the relationship between randomized controlled clinical trial efficacy data and real-world effectiveness for oncology therapies.